A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.

被引：0
|
作者：
Gutierrez, Martin
Giaccone, Giuseppe
Harper, Harry D.
Liu, Stephen V.
Fang, Bruno
Ruiz, Jimmy
Hinson, James M.
Orlemans, Everardus Otto
Drilon, Alexander E.
机构：
[1] Hackensack Univ, Med Ctr, Reg Canc Care Associates, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Reg Canc Care Associates LLC, East Brunswick, NJ USA
[4] Wake Forest, Ctr Comprehens Canc, Winston Salem, NC USA
[5] Unicorn Pharma Consulting, Nashville, TN USA
[6] Esanex Inc, Indianapolis, IN USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19033
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
    Gutierrez, M. E.
    Giaccone, G.
    Liu, S. V.
    Rajan, A.
    Guha, U.
    Halfdanarson, T. R.
    Curtis, K. K.
    Kunz, P. L.
    Gabrail, N.
    Hinson, J. M.
    Orlemans, E. O.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs)
    Gutierrez, Martin E.
    Giaccone, Giuseppe
    Liu, Stephen V.
    Rajan, Arun
    Guha, Udayan
    Halfdanarson, Thorvardur
    Kunz, Pamela
    Hinson, James M., Jr.
    Orlemans, Everardus O.
    PANCREAS, 2018, 47 (03) : 339 - 339
  • [3] Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers
    Gutierrez, Martin
    Guo, Robin
    Giaccone, Giuseppe
    Liu, Stephen V.
    Hao, Zhonglin
    Hilton, Christie
    Hinson, James M., Jr.
    Kris, Mark G.
    Orlemans, Everardus Otto
    Drilon, Alexander
    LUNG CANCER, 2021, 162 : 23 - 28
  • [4] A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
    Bryson, J. C.
    Infante, J. R.
    Ramanathan, R. K.
    Jones, S. F.
    Von Hoff, D. D.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase 1B study of SNX-5422 plus carboplatin (C) and paclitaxel (P) in patients with advanced non-small-cell lung cancer (NSCLC)
    Gutierrez, Martin
    Giaccone, Giuseppe
    Liu, Stephen V.
    Hao, Zhonglin
    Hilton, Christie
    Hinson, James M.
    Orlemans, Everardus Otto
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    du Bois, A.
    Huober, J.
    Stopfer, P.
    Pfisterer, J.
    Wimberger, P.
    Loibl, S.
    Reichardt, V. L.
    Harter, P.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 370 - 375
  • [7] Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
    Kollmannsberger, C.
    Hirte, H.
    Siu, L. L.
    Mazurka, J.
    Chi, K.
    Elit, L.
    Walsh, W.
    Sederias, J.
    Doyle, A.
    Eisenhauer, E. A.
    Oza, A. M.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 238 - 244
  • [8] A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers
    Rubinstein, Maria M.
    Grisham, Rachel N.
    Cadoo, Karen
    Kyi, Chrisann
    Tew, William P.
    Friedman, Claire F.
    O'Cearbhaill, Roisin E.
    Zamarin, Dmitriy
    Zhou, Qin
    Iasonos, Alexia
    Nikolovski, Ines
    Xu, Hongmei
    Soldan, Krysten N.
    Caird, Imogen
    Martin, Madhuri
    Guillen, Joyce
    Eid, Khalil T.
    Aghajanian, Carol
    Makker, Vicky
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 71 - 76
  • [9] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [10] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
12345